The US Food and Drug Administration continued a recent device classification spree with five further Federal Register announcements this week.
Four of the de novo devices being classified were placed in moderate-risk class II, while a pressure ulcer management tool...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?